Inclusion Criteria:

- Histologically proven recurrent transitional cell carcinoma of the bladder, Stage
Tis, Ta.

- Patients with recurrent T1 disease who do not wish to have cystectomy.

- Subjects must have failed at least two prior courses of BCG with or without
recombinant interferon alpha administration.

- At least 3 months must have passed since last intravesical treatment for bladder
carcinoma.

- Subjects must be 18 years of age or older.

- Life expectancy of at least 3 months.

- Adequate performance status (Karnofsky score >=70%).

- Adequate laboratory values.

Exclusion Criteria:

- Suspected hypersensitivity to interferon alpha.

- Subjects with organ transplants.

- Any known preexisting medical condition that could interfere with the subject's
participation in and completion of the study such as:

- History of psychosis or presence of poorly controlled depression;

- CNS trauma or active seizure disorders requiring medication;

- Significant cardiovascular dysfunction within the past 6 months including
symptomatic cardiac ischemia, arrhythmia or congestive heart failure requiring
hospitalization or emergency room visit within last 3 months;

- Poorly controlled diabetes mellitus (HbA1C >10.0%);

- Unstable chronic pulmonary disease requiring hospitalization or emergency room
visit within the last 3 months;

- Immunologically mediated disease (eg, rheumatoid arthritis, autoimmune
hepatitis, immune mediated glomerulonephritis).

- History of any clinically significant local or systemic infectious disease within 4
weeks prior to initial treatment administration.

- Untreated bladder infection.

- Positive for hepatitis BsAg or HIV Ab or hepatitis C.

- Immunosuppressive therapy within the last 3 months.

- BCG therapy or intravesical therapy within 3 months.

- Traumatic catheterization within 1 month.